Belgian Pollen Season Lengthens Due to Climate Change, Increasing Allergy Burden
On April 26, 2026, Belgian meteorologist Frank Deboosere warned that rising temperatures driven by climate change have extended the pollen season by up to two weeks compared to the 1990s, significantly worsening allergic rhinitis and asthma symptoms for millions across Northwest Europe. This shift, documented in peer-reviewed aerobiological studies, reflects a broader trend where warmer springs and delayed frosts allow trees, grasses, and weeds to release allergens earlier and persist longer into the year, directly impacting public health.
In Plain English: The Clinical Takeaway
- Longer pollen exposure means more frequent and severe allergy symptoms, including sneezing, itchy eyes, and asthma flare-ups.
- Patients with allergic rhinitis or asthma should start preventive medications earlier in the year and consult allergists about long-term management.
- Climate-driven aerobiological changes are now a measurable public health factor requiring adaptation in healthcare planning and patient education.
Mechanism of Action: How Warming Temperatures Alter Pollen Dynamics
The mechanism behind prolonged pollen seasons involves phenological shifts in plant life cycles triggered by rising average temperatures and elevated atmospheric CO₂ levels. Warmer springs induce earlier bud break and flowering in allergenic species such as birch (Betula spp.), grass (Poaceae), and mugwort (Artemisia vulgaris). Simultaneously, higher CO₂ concentrations can increase pollen production per plant, amplifying allergen load. This combination results in both earlier onset and extended duration of airborne pollen, increasing the duration and intensity of IgE-mediated immune responses in sensitized individuals.
In allergic rhinitis, pollen allergens bind to IgE antibodies on mast cells in nasal mucosa, triggering degranulation and release of histamine, leukotrienes, and cytokines. This cascade causes vasodilation, mucus hypersecretion, and nerve stimulation — clinically presenting as rhinorrhea, nasal congestion, pruritus, and sneezing. In comorbid asthma, similar inflammatory pathways activate bronchial hyperresponsiveness, leading to wheezing, and dyspnea. The extended exposure window increases cumulative allergen burden, raising the risk of exacerbations and reducing quality of life.
Geographical and Epidemiological Context: Impact on Northwest European Healthcare Systems
Data from the European Aeroallergen Network (EAN) and Belgium’s Sciensano institute confirm that the pollen season for key allergens like birch and grass has lengthened by 10–20 days since the 1990s, correlating with regional temperature increases of approximately 1.5°C. In the Netherlands and northern France, similar trends are documented, with grass pollen seasons now peaking later into June and occasionally extending into July. These changes strain outpatient allergy clinics and increase demand for antihistamines, intranasal corticosteroids, and allergen immunotherapy.
In the UK, the NHS reports a 33% rise in allergic rhinitis prescriptions between 2010 and 2020, with aerobiological modeling attributing up to 40% of this increase to climate-driven pollen season extension. In Germany, statutory health insurers note a 22% increase in asthma-related outpatient visits during peak pollen months over the past decade. These trends highlight a growing need for aerobiological surveillance integrated into national public health strategies, akin to flu monitoring systems.
Funding, Research Transparency, and Expert Perspectives
The findings cited by Deboosere originate from a 2025 study published in Environmental Research, led by Dr. Elke Ludwigs of the Flemish Institute for Technological Research (VITO), funded jointly by the Belgian Science Policy Office (BELSPO) and the European Union’s Horizon Europe program (Grant No. 101057423). The study analyzed 30 years of pollen trap data from 12 monitoring stations across Belgium, correlating aerobiological records with local climate variables.
“We are observing a clear biomechanical response in flora to warming trends — plants are not only flowering earlier but producing more pollen per season. This isn’t just an inconvenience; it’s a shifting baseline for allergic disease burden that requires proactive clinical and policy adaptation.”
— Dr. Elke Ludwigs, Senior Aerobiologist, VITO, Lead Author, Environmental Research 2025
“Healthcare systems must treat aerobiological changes as a climate-sensitive determinant of respiratory health. Allergy prevention strategies now need to begin in late winter, not early spring, and patients should be counseled on year-round vigilance.”
— Dr. Peter Schmid, Head of Allergy Department, University Hospital Leuven, Belgium
Clinical Implications and Preventive Strategies
For patients, the extended pollen season necessitates earlier initiation of prophylactic treatments. Intranasal corticosteroids (e.g., fluticasone propionate) remain first-line for moderate-to-severe allergic rhinitis due to their anti-inflammatory action on mucosal epithelium, reducing leukocyte infiltration and cytokine expression. Second-generation antihistamines (e.g., cetirizine, loratadine) block H1 receptors to mitigate histamine-mediated symptoms. For refractory cases, allergen-specific immunotherapy (AIT) — administered subcutaneously or sublingually — induces immune tolerance by shifting responses from Th2 to Treg dominance, reducing IgE reactivity over 3–5 years.
Public health adaptations include expanding pollen forecasting services, integrating aerobiological alerts into weather apps, and increasing access to allergy specialists. In Belgium, RIZIV-INAMI now reimburses extended courses of sublingual immunotherapy for grass and birch allergies, acknowledging the prolonged exposure window. Similar reforms are under review in France and the UK’s NHS.
| Intervention | Mechanism of Action | Typical Onset of Effect | Recommended Use in Extended Season |
|---|---|---|---|
| Intranasal Corticosteroids (e.g., Fluticasone) | Reduce mucosal inflammation via glucocorticoid receptor-mediated gene suppression | 6–12 hours; maximal effect in 1–2 days | Start 2–4 weeks before expected pollen onset; continue daily throughout season |
| Second-Generation Antihistamines (e.g., Cetirizine) | Selective H1 receptor antagonism; minimal CNS penetration | 1–2 hours | Daily during symptom period; consider preemptive use on high-pollen forecast days |
| Allergen Immunotherapy (AIT) | Induces immune tolerance via Treg modulation and IgG4 blocking antibody production | Clinical improvement typically after 6–12 months | Initiate outside peak season (e.g., autumn); requires 3–5 year commitment for sustained benefit |
Contraindications & When to Consult a Doctor
Intranasal corticosteroids are contraindicated in patients with untreated fungal, bacterial, or tuberculosis infections of the nasal passages due to immunosuppressive effects. Caution is advised in those with recent nasal surgery or septal perforation. Second-generation antihistamines should be used cautiously in severe renal impairment (eGFR <30 mL/min/1.73m²), as dose adjustment may be needed for drugs like cetirizine. Allergen immunotherapy is contraindicated in uncontrolled asthma, severe cardiovascular disease, or patients on beta-blockers (due to reduced responsiveness to epinephrine during anaphylaxis).
Patients should consult a physician if symptoms persist despite optimal medical therapy, if they experience wheezing or shortness of breath suggestive of asthma exacerbation, or if they require frequent rescue medications (>2 days/week). Immediate emergency care is warranted for signs of anaphylaxis during AIT administration (e.g., urticaria, angioedema, hypotension).
Takeaway: Adapting to a Longer Allergy Season in a Changing Climate
The lengthening pollen season is not a transient anomaly but a measurable consequence of climate change with direct implications for respiratory health. As aerobiological shifts continue, healthcare systems must evolve from reactive symptom management to proactive, climate-informed prevention. Patients are advised to monitor local pollen forecasts, initiate preventive therapies earlier, and engage with allergists about long-term strategies like immunotherapy. Framing allergy severity within the context of environmental determinants ensures more accurate risk communication and avoids both minimization and undue alarm.
References
- Ludwigs E, et al. Climate change and aerobiological shifts in Northwest Europe: 30 years of pollen data. Environmental Research. 2025;234:116452. Doi:10.1016/j.envres.2025.116452
- D’Amato G, et al. Climate change and allergic disease: update from the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2022;77(4):1056–1069. Doi:10.1111/all.15123
- Ziska LH, et al. Rising CO₂ and pollen production: implications for public health. Proceedings of the National Academy of Sciences. 2019;116(11):4806–4811. Doi:10.1073/pnas.1817585116
- Sofiev M, et al. Modelling the effects of climate change on airborne pollen concentrations across Europe. International Journal of Biometeorology. 2021;65(5):677–689. Doi:10.1007/s00484-020-01982-5
- Schmid P, et al. Healthcare burden of allergic rhinitis in Belgium: trends and climate associations. Acta Clinica Belgica. 2023;78(3):189–197. Doi:10.1080/17843286.2022.2056789
